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Background: Olfactory dysfunction is present in a large proportion of patients with Parkinson's disease
(PD) upon diagnosis. However, its progression over time has been poorly investigated. The few available
longitudinal studies lack control groups or MRI data.
Objective: To investigate the olfactory changes and their structural correlates in non-demented PD over a
four-year follow-up.
Methods: We assessed olfactory function in a sample of 25 PD patients and 24 normal controls of similar
age using the University of Pennsylvania Smell Identification test (UPSIT). Structural magnetic resonance
imaging data, obtained with a 3-T Siemens Trio scanner, were analyzed using FreeSurfer software.
Results: Analysis of variance showed significant group (F ¼ 53.882; P < 0.001) and time (F ¼ 6.203;
P ¼ 0.016) effects, but the group-by-time interaction was not statistically significant. UPSIT performance
declined 1.5 standard deviations in 5 controls and 7 patients. Change in UPSIT scores of patients
correlated positively with volume change in the left putamen, right thalamus, and right caudate nucleus.
Conclusion: Olfactory loss over time in PD and controls is similar, but we have observed significant
correlation between this loss and basal ganglia volumes only in patients.
© 2017 Elsevier Ltd. All rights reserved.1. Introduction
Olfactory dysfunction is very frequent in PD. This impairment
can already be observed in de novo patients, and is unrelated to
dopaminergic treatment [1]. In a multicenter study, the prevalence
of olfactory deficits was estimated to be 96.7%when comparedwith
young subjects, and 74.5% when adjusted for age [2]. However, the
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severe hyposmia. It has been suggested that normosmic patients
could be a unique clinical phenotype with fewer motor deficits and
a more benign disease course [3]. In contrast, severe olfactory
dysfunctions have been associated with worse cognitive perfor-
mance, more cognitive decline over time, and higher risk of pro-
gression to mild cognitive impairment (MCI) and to dementia
[4e6].
Olfactory impairment is observed in de novo patients and can
therefore occur regardless of dopaminergic treatment [7,8]. Olfac-
tory dysfunction has also been found to be a preclinical or premotor
manifestation in PD [1,9]. In a study of asymptomatic relatives of PD
patients, it has been found that hyposmia is associated with a 12.5%
risk of developing PD within a five-year period [10]. Similarly, pa-
tients diagnosed with idiopathic anosmia are at a higher risk of
developing PD [11]. Moreover, hyposmia is observed in patients
with idiopathic REM sleep behavior disorder, a prodromal PD
symptom [12].
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sectional studies are inconsistent, with some suggesting that ol-
factory loss does not progress over the course of PD since it does not
correlate with disease duration [1,13,14]. Nonetheless, correlations
with disease severity and symptom durationwas also reported [15].
The lack of worsening in olfaction is consistent with Braak staging
describing the olfactory bulb as a region affected in the first stages
of the disease [16]. However, the progression of degenerative
changes in other regions involved in olfaction might contribute to
increase the degree of olfactory impairment. Results from post-
mortem studies revealed pathological changes (Lewy body for-
mation) in the olfactory bulb but also in other brain regions such as
the anterior olfactory nucleus, the piriform cortex, the amygdaloid
complex, the entorhinal cortex, and the hippocampal formation [1].
In agreement with the involvement of several regions explaining
olfactory deficits in PD, MRI studies have reported correlations of
olfactory deficits with olfactory bulb volume [17e19], but also with
piriform and orbitofrontal cortical volumes [20,21].
To the best of our knowledge, only three longitudinal studies of
olfactory deficits in PD have been published [22e24]. These studies
did not include a control group, which makes it difficult to distin-
guish disease-related decline from the effects of aging on olfactory
function [25]. Moreover, there are no previous longitudinal studies
including MRI data. In the current work, we investigated the ol-
factory changes in a sample of patients compared with a control
group of similar age. We also performed correlation analyses be-
tween olfactory loss and measures of brain atrophy.
2. Method
2.1. Participants
The study sample included 25 PD patients and 24 healthy con-
trols (HC) who underwent olfactory and MRI evaluation twice.
These subjects are part of a cohort of 98 PD patients and 33 HC
recruited between October 2010, and March 2012. In the present
study, we only included subjects who underwent olfactory andMRI
evaluation at both time points. In the 2010 cohort, the UPSIT was
only administered to a small subsample. The mean (±standard
deviation) follow-up interval was 44.9 ± 5.7 months for patients
and 45.9 ± 3.5 months for controls (F ¼ 0.732; P ¼ 0.468). Inclusion
criteria for patients at time 1 were: (1) the fulfillment of UK PD
Society Brain Bank diagnostic criteria for PD; (2) no surgical treat-
ment with deep brain stimulation. Exclusion criteria were: (1) de-
mentia according to Movement Disorders Society criteria; (2)
Hoehn and Yahr (H&Y) score > 3; (3) significant psychiatric,
neurological, or systemic comorbidity; (4) low global intelligence
quotient estimated by the Vocabulary subtest of theWechsler Adult
Intelligence Scale, 3rd edition (scaled score  7); (5) Mini Mental
State Examination (MMSE) score < 25; (6) presence of claustro-
phobia; (7) significant pathological MRI findings other than mild
white matter hyperintensities in the FLAIR sequence; (8) MRI
artefacts.
All PD patients were taking antiparkinsonian medication con-
sisting of different combinations of L-DOPA, COMT inhibitors, MAO
inhibitors, dopamine agonists, and amantadine. In order to stan-
dardize doses, levodopa equivalent daily dose (LEDD) was calcu-
lated as suggested by Tomlinson et al. [26] All assessments were
done in the on state. Motor disease severity was evaluated using
H&Y staging and the Unified Parkinson's Disease Rating Scale
motor section (UPDRS-III).
The study was approved by the Ethics Committee of the Uni-
versity of Barcelona (IRB00003099). All subjects provided written
informed consent to participate after full explanation of the pro-
cedures involved.2.2. Olfactory and clinical assessment
Odor identification was assessed using the Spanish version of
the University of Pennsylvania Smell Identification Test [27]. The
UPSIT is a standardized multiple-choice scratch-and-sniff test
consisting of four test booklets with 10 items each. Subjects
scratched the impregnated area and were asked to select from one
of four possible answers for each item. If the patient could not
identify an odor, and the examiner observed that the area was not
sufficiently scratched, the examiner either scratched the area or
suggested that the patient do so until an odor was selected. Sub-
jects were also asked for their smoking history and whether they
were aware of having any smell dysfunction. Following normative
data presented in the UPSIT manual, which includes adjustment for
age and sex, scores greater than 33 in males and 34 in females were
considered to reflect normosmia, and scores lower or equal to 18
reflected anosmia. Olfactory decline was established if the total
UPSIT score was at least 1.5 standard deviation (based on the dis-
tribution of scores in the HC group at baseline) lower at time 2 than
at time 1.
Participants were assessed with a neuropsychological battery
recommended by the Movement Disorder Society task force to
evaluate cognitive functions in PD [28]. Attention and working
memory were assessed with the Trail Making Test (TMT) (in sec-
onds), part A (TMT A) and part B (TMT B), Digit Span Forward and
Backward, and the Stroop Color-word Test and Symbol Digits Mo-
dalities Tests (SDMT); executive functions were evaluated with
phonemic (words beginning with the letter “p” in 1 min) and se-
mantic (animals in 1 min) fluencies; language was assessed by the
total number of correct responses in the short version of the Boston
Naming Test; and memory through total learning recall (sum of
correct responses from trial I to trial V) and delayed recall (total
recall after 20 min) using Rey's Auditory Verbal Learning Test
(RAVLT). Visuospatial and visuoperceptual functions were assessed
with Benton's Judgement of Line Orientation (JLO) and Visual Form
Discrimination (VFD) tests.
As in a previous study [29], the presence of MCI was established
if the z-score for a given test was at least 1.5 lower than the ex-
pected score in at least two tests in one domain, or in at least one
test per domain in at least two domains. Furthermore, the presence
of dementia was determined if MMSE score was below 25, or if
there was cognitive impairment in more than one domain and
impaired instrumental activities of daily living (IADL), as recom-
mended by Dubois et al. [30].
The Beck Depression Inventory II, Starkstein's Apathy Scale, and
the Neuropsychiatric Inventory were administered to all subjects to
explore the presence of psychiatric symptoms.
2.3. MRI analyses
2.3.1. Preprocessing of longitudinal imaging data
MRI data were acquired with a 3T scanner (MAGNETOM Trio,
Siemens, Germany) at both times. The scanning protocol included
high-resolution 3-dimensional T1-weighted images acquired in the
sagittal plane (TR ¼ 2300 ms, TE ¼ 2.98 ms, TI ¼ 900 ms, 240 slices,
FOV ¼ 256 mm; 1 mm isotropic voxel) and an axial FLAIR sequence
(TR ¼ 9000 ms, TE ¼ 96 ms).
Cross-sectional preprocessing of both times was performed
using the automated FreeSurfer stream (version 5.1; available at:
http://surfer.nmr.harvard.edu) as previously described in Segura
et al. [29]. Detailed information about the longitudinal FreeSurfer
stream is described in Ibarretxe-Bilbao et al. [31].
Longitudinal cortical thickness comparisons were performed
using the longitudinal two-stage model. In this analysis, we
computed the symmetrized percent of change (SPC) of cortical
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ness2-thickness1)/(time2-time1)) with respect to the average
thickness (0.5*(thickness1þthickness2)). In aging or disease, SPC is
expected to be negative in most regions (https://surfer.nmr.mgh.
harvard.edu/fswiki/LongitudinalTwoStageModel). We also ob-
tained striatal (putamen and caudate) volumes via whole-brain
segmentation.
Comparisons between groups were performed using a vertex-
by-vertex general linear model. One-sample t-tests were per-
formed to test time effects in both groups (if the SPC was different
from zero). To test group-by-time interaction effects, SPC was
included as a dependent factor and group as an independent factor
(Supplementary Table 1).
In addition, supplementary cross-sectional intergroup cortical
thickness comparisons were performed using a vertex-by-vertex
general linear model with FreeSurfer at time 1 and time 2
(Supplementary Table 1).
All results were corrected for multiple comparisons using pre-
cached cluster-wise Monte Carlo simulation with 10,000 itera-
tions. Simulation was applied for negative time effects (time
2 < time 1) in each group, whereas, on all other models, simulation
was applied for absolute results. Reported cortical regions reached
one-tailed and two-tailed corrected significance level of p < 0.05
respectively.
The SPC of striatal volumes was computed and introduced in
independent t-tests in order to compare it between groups. Sig-
nificant results were corrected by general cognitive status (MMSE),
age and gender. The SPC of UPSIT scores was also calculated.
Pearson's correlation test was used to study the relationship be-
tween SPC of striatal volumes and SPC of UPSIT scores, and control
of the false-discovery rate to 5% (FDR) was used to correct for
multiple testing [32].
2.4. Statistical analyses of demographic, clinical, and olfactory data
Statistical analyses of demographic, clinical, and olfactory data
were performed using IBM SPSS Statistics 22.0.0 (2013; Armonk,
NY: IBM Corp). Group differences in demographic and clinical
variables between HC and PD patients were analyzed with inde-
pendent t-tests for quantitative measures or with Pearson's chi-
squared test for categorical measures. Mann-Whitney's U test was
used when comparing PD with olfactory decline and PD non-Table 1
Demographic and clinical characteristics of PD patients and HC at both times.
PD (n ¼ 25)
Age at baseline, yrs., mean (SD) 61.4 (10.0)
Education, yrs., mean (SD) 12.9 (4.8)
Vocabulary subtest, mean (SD) 49.0 (6.8)
Sex, male, n (%) 14 (56.0)
Disease duration, yrs., mean (SD)
Time 1 4.9 (3.5)
Time 2 8.7 (3.4)
Age of onset, yrs., mean (SD) 56.4 (10.3)
UPDRS part III, mean (SD)
Time 1 14.04 (8.7)
Time 2 16.25 (7.7)
Hoehn & Yahr stage, n 1/1.5/2/2.5/3/4
Time 1 9/1/12/2/1/0
Time 2 4/0/11/0/10/0
LEDD, mg, mean (SD)
Time 1 607.8 (433.4)
Time 2 659.2 (371.4)
Abbreviations: HC: healthy controls; LEDD: L-dopa equivalent daily dose; NA: not a
Rating Scale motor section. Data are presented as mean (SD) or n (%).
a Independent t-tests were used for continuous variables when comparing HC wi
b Pearson's chi-squared tests were used for categorical variables.decliners, due to small subsamples. In order to study the relation-
ship between clinical and olfactory data, Pearson's correlation co-
efficient test was used. Group-by-time interaction effects in clinical
variables such as UPSIT, neuropsychological tests, and neuropsy-
chiatric symptoms between PD and HC were assessed through a
repeated-measures general linear model.
3. Results
3.1. Demographic and clinical characteristics
There were no differences between groups in age (t ¼ 1.468;
P ¼ 0.149), years of education (t ¼ 1.235; P ¼ 0.223), estimated IQ
scores (t ¼ 1.045; P ¼ 0.301), or sex (X2 ¼ 0.506; P ¼ 0.477).
Regarding psychiatric symptoms, there were no significant in-
teractions between group and time in Beck Depression Inventory II
(F ¼ 1.777; P ¼ 0.190), Starkstein's Apathy Scale (F ¼ 0.090;
P ¼ 0.766), or in Cummings' Neuropsychiatric Inventory scores
(F ¼ 0.992; P ¼ 0.325) (Table 1).
Significant interactions between group and time were found in
Stroop Color (F ¼ 5.445; P ¼ 0.024), Stroop Word-Color (F ¼ 5.121;
P¼ 0.029), SDMT (F¼ 8.107; P¼ 0.007), and the short version of the
BNT (F ¼ 5.077; P ¼ 0.029). At follow-up, PD-MCI criteria were
fulfilled by 12 (25%) patients, from whom 6 were cognitively pre-
served at baseline. Two (4.1%) PD-MCI patients had converted to PD
dementia at follow-up.
3.2. Olfactory decline over time
Table 2 shows the UPSIT performance at baseline and after four
years of follow-up. The distribution of the degree of impairment in
PD patients in the first assessment was 36% anosmics, 60% hypos-
mics, and 4% normosmic. Repeated-measures analysis showed a
significant effect of group (F ¼ 53.882; P < 0.001) and time
(F ¼ 6.203; P ¼ 0.016), but the group-by-time interaction did not
achieve statistical significance (F ¼ 0.277; P ¼ 0.601).
In patients, UPSIT scores correlated significantlywith age at time
1 (r ¼ 0.469; P ¼ 0.018), and with years of disease duration
(r¼0.434; P¼ 0.030) and LEDD (r¼0.463; P¼ 0.020) at time 2.
Qualitatively taking the cut-off of 1.5 standard deviation decline
from the baseline scores, 5 controls and 7 patients displayed sig-














pplicable; PD: Parkinson's disease; UPDRS part III: Unified Parkinson's Disease
th all PD patients.
Table 2
Olfactory results in PD and HC at both times.
PD (n ¼ 25) HC (n ¼ 24) Test stats/P-value
University of Pennsylvania Smell Identification Test
Time 1, mean (SD) 20.6 (7.5) 31.3 (3.1) 6.481/<0.001a
Time 2, mean (SD) 18.7 (6.4) 30.0 (4.7) 7.036/<0.001a
Olfactory status according to UPSIT, n (%)
Time 1 Anosmics 9 (36.0) 0 (0.0)
Time 2 Anosmics 12 (48.0) 0 (0.0)
Abbreviations: HC, healthy controls; PD, Parkinson's disease; UPSIT, University of Pennsylvania Smell Identification Test. Data are presented as mean (SD) or n (%).
a Independent t-tests were used for continuous variables when comparing HC with all PD patients.
A. Campabadal et al. / Parkinsonism and Related Disorders 41 (2017) 44e50 47decline did not differ from non-decliners in any clinical or de-
mographic variable.3.3. Cortical thickness and volumetric changes
Comparison of whole-brain cortical thickness maps showed that
both groups had significant progressive cortical thinning in severalFig. 1. Abbreviations: HC: healthy controls; PD: Parkinson’s disease. Results were obtained us
provide cluster-wise correction for multiple comparisons. Simulation was applied for nega
shown.regions of the posterior cortex. In PD patients, significant cortical
thinning was found in the left isthmus of the cingulate gyrus and in
the right inferior parietal lobule. ln controls, changes over time
were seen in the left lingual gyrus and insula, and in the right
caudal middle frontal gyrus and lateral occipital regions (Fig. 1). No
significant group-by-time interactions were seen between controls
and patients.ing Monte Carlo simulation with 10,000 iterations applied to cortical thickness maps to
tive time effects (time 2 < time 1) in each group. Clusters with corrected p < .05 are
A. Campabadal et al. / Parkinsonism and Related Disorders 41 (2017) 44e5048The analysis of volumetric changes in the regions of interest of
the olfactory system showed that PD patients had greater per-
centage of volume loss in the right putamen in comparisonwith HC
(t ¼ 2.676; P ¼ 0.010). Differences remain significant after con-
trolling for general cognitive status, age, and gender (F ¼ 6.504;
P ¼ 0.014).
Correlations between the percentage of change in UPSIT scores
and basal ganglia volumes, corrected for multiple comparisons
using FDR, showed statistical significance for PD patients in the
right thalamus (P ¼ 0.044), right caudate (P ¼ 0.049), and left pu-
tamen (P ¼ 0.044) (Fig. 2).
Regarding changes in subcortical volumes over time, PD with
olfactory decline had greater right caudate loss in comparison with
PD without olfactory decline (U ¼ 22.000; P ¼ 0.012).4. Discussion
Our results demonstrate that olfactory impairments progress
over time in PD patients, as we detected significant worsening after
four years of follow-up. However, the progression of smell
impairment was similar to that identified in the control group.
These results seem to suggest that aging per se could be responsible
for the observed changes in olfactory ability. An alternative expla-
nation could be that atrophy in different brain structures might
produce similar clinical changes.
In our study, the prevalence of olfactory deficits as well as the
mean scores observed in patients and controls are similar to pre-
vious reports using UPSITwith larger samples [1]. Our sample could
thus be considered representative of olfactory dysfunctions in PD.
We found that the distribution of the degree of impairment in PD
patients in the first assessment was 36% anosmics, 60% hyposmics,
and 4% normosmic. Regarding the decline in olfactory performance,
our results agree with those from a previous longitudinal study
performed in a sample of 19 PD patients studied twice with an
interval of five years using the “sniffin’ sticks”; in that study,
however, aging effects could not be excluded because the authors
did not include a control group in the design [24]. In the present
study, we found a significant effect of time during the four-year
follow-up in both patients and controls. The scores obtained in
the UPSIT diminished a mean of two points in PD patients, and 1.3
points in HC. Taking the cut-off point of 1.5 standard deviationFig. 2. Significant correlation between the percentages of change in UPSITbelow the baseline score as indicative of decline, we observed ol-
factory decline in 7 patients, but also in 5 controls. It is well known
that aging per se is associated with olfactory decline; McKinnon
et al. (2010), using data collected from 732 subjects, estimated that
the decrease in UPSIT scores is 3.2 points for every 10 years of age
[33]. Loss of olfactory identification ability is seen from the 5th
decade onwards, but is most remarkable between the 7th and 8th
decades of life [25]. The correlations between UPSIT scores and
disease duration that we and other researchers have observed
could reflect both aging effects and the progression of the degen-
erative process.
In the current four-year longitudinal study, we found evidence
of progressive cortical thickness reduction, but this atrophy was
similar for patients and controls, and was unrelated to the olfactory
loss. From a neuropathological point of view, the severity of
abnormal protein aggregates (including alpha-synuclein, hyper-
phospholylated tau protein, and neurofilament protein) in the ol-
factory bulb and tract increases significantly in neurodegenerative
diseases with increasing neuritic Braak stages and McKeith criteria
for Lewy body disease [34]. Odor impairment in PD may be due to
defective adult neurogenesis. In animal models, dopaminergic
deafferentation may result in impaired precursor cell proliferation
in the subventricular zone, which provides new olfactory bulb
neurons. It also results in an increased number of dopaminergic
neurons in the glomerular cell layer of the olfactory bulb. In PD, the
survival of newly generated neurons in the bulb is decreased [35].
Moreover, it has been experimentally demonstrated that dopamine
modulates adult neurogenesis in vivo and in vitro and that adult
neurogenesis is impaired in individuals with PD [36].
It is thus clear that there is a neuropathological basis for pro-
gressive odor impairment. Regarding its anatomical correlates, ol-
factory impairment in PD has been associated with atrophy of the
olfactory bulb [17e19], piriform cortex [21,37], and orbitofrontal
cortex [21]. The gray matter correlates of olfactory deficits differ
according to the disease stage; in early PD patients, significant
correlations are seen in the right piriform cortex, while inmoderate
and advanced patients the right amygdala is implicated [37]. Ac-
cording to Braak stages [16], the orbitofrontal cortex, a tertiary ol-
factory structure, is affected relatively early, and prior to posterior
parietal regions. Changes in orbitofrontal cortex are therefore ex-
pected in early disease stages. Lack of change over the study time inscores and subcortical volumes. SPC: symmetrized percentage change.
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gression of Lewy-type lesions proposed by the Braak staging. It is
possible that further longitudinal studies in de novo samples could
help identify the relationship between orbital frontal atrophy and
loss of odor identification.
In contrast to the lack of cortical correlates of smell loss in PD,
we observed significant correlations between the percentage of
change in UPSIT scores and the percentage of volume loss in some
striatal regions related to the olfactory system. In normal subjects,
PET studies showed activation in the thalamus and right caudate
during olfactory perception [38]. In fMRI studies, activation was
reported in the left putamen [39,40] and caudate [40]. In PD, odor
perception activates the bilateral putamen [39], left caudate, and
left putamen [40]. Thus, although the striatal nuclei are not clas-
sically considered as olfactory structures, they appear to be part of
circuitry involved in olfactory perception. Moreover, olfactory
performance in PD have been reported to be correlated with gray
matter density in the caudate and putamen [41]. However, an
alternative interpretation of our results is that striatal atrophy may
reflect the rapid disease progression in PD with severe olfactory
impairment. In a cross-sectional study, it has been observed that
abnormal odor identification was associated with more advanced
stages of PD and increased severity of motor symptoms [42].
Similarly, it has been reported that regional mean diffusivity values
of the substantia nigra and the olfactory tract correlated signifi-
cantly with putaminal dopaminergic dysfunction [43].
In conclusion, PD patients and healthy controls matched by age
showed a significant similar progressive olfactory loss and a pro-
gressive reduction of cortical thickness mainly involving posterior
regions, but olfactory loss was associatedwith basal ganglia volume
reductions only in PD.
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